Vascular endothelial growth factor gene therapy - Biosidus S.A.Alternative Names: VEGF GENE Therapy - Biosidus S.A.
Latest Information Update: 21 Jan 2016
$50 / €47 *
At a glance
- Originator Biosidus S.A.
- Class Cytokine genes; Gene therapies; Growth factors
- Mechanism of Action Angiogenesis inducing agents; Gene transference; Vascular endothelial growth factor A stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Ischaemic heart disorders
Most Recent Events
- 21 Jan 2016 Phase-I development is ongoing in Argentina
- 17 Sep 2013 Phase-I clinical trials in Ischaemic heart disorders in Argentina before 17 Sep 2013 (Intramyocardial)
- 17 Sep 2013 Preclinical trials in Ischaemic heart disorders in Argentina before 17 Sep 2013 (Intramyocardial)